Ondansteron: Difference between revisions
Elcatracho (talk | contribs) |
Ostermayer (talk | contribs) (Prepared the page for translation) |
||
| Line 1: | Line 1: | ||
<languages/> | |||
<translate> | |||
==General== | ==General== | ||
*Type: [[antiemetics]] | |||
*Type: [[Special:MyLanguage/antiemetics|antiemetics]] | |||
*Dosage Forms: 4mg, 8mg | *Dosage Forms: 4mg, 8mg | ||
*Common Trade Names: Zofran | *Common Trade Names: Zofran | ||
==Adult Dosing== | ==Adult Dosing== | ||
*Nausea/Vomiting: 4-8mg q4h, max 24mg a day | *Nausea/Vomiting: 4-8mg q4h, max 24mg a day | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*Nausea/Vomiting: 0.1mg/kg IV q4h max dose at once:4-8mg, max 24mg | *Nausea/Vomiting: 0.1mg/kg IV q4h max dose at once:4-8mg, max 24mg | ||
*Gastroenteritis - Vomiting | *Gastroenteritis - Vomiting | ||
| Line 15: | Line 23: | ||
**Greater than 30 kg: | **Greater than 30 kg: | ||
***8mg orally disintegrating tablet dissolved orally as a single dose | ***8mg orally disintegrating tablet dissolved orally as a single dose | ||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B | |||
*[[Special:MyLanguage/Drug Ratings in Pregnancy|Pregnancy Rating]]: B | |||
**Consider avoiding in 1st trimester; conflicting data regarding possible risk of teratogenicity | **Consider avoiding in 1st trimester; conflicting data regarding possible risk of teratogenicity | ||
**Newer data argues that ondansetron is not the cause of birth defects<ref>Fejzo MS, et al. Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States. Reprod Toxicol. 2016 Jul;62:87-91.</ref> | **Newer data argues that ondansetron is not the cause of birth defects<ref>Fejzo MS, et al. Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States. Reprod Toxicol. 2016 Jul;62:87-91.</ref> | ||
| Line 27: | Line 37: | ||
**Adult: not defined | **Adult: not defined | ||
**Pediatric: not defined | **Pediatric: not defined | ||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug | ||
*Congenital long QT syndrome | *Congenital long QT syndrome | ||
*Serotonin syndrome | *Serotonin syndrome | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*bronchospasm | *bronchospasm | ||
*steven-johnson syndrome | *steven-johnson syndrome | ||
| Line 42: | Line 58: | ||
*extrapyramidal symptoms | *extrapyramidal symptoms | ||
*blindness, transient | *blindness, transient | ||
===Common=== | ===Common=== | ||
*headache | *headache | ||
*constipation | *constipation | ||
| Line 50: | Line 68: | ||
*urinary retention | *urinary retention | ||
*agitation | *agitation | ||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: 4.6-5.7 hour | *Half-life: 4.6-5.7 hour | ||
*Metabolism: liver | *Metabolism: liver | ||
*Excretion: urine | *Excretion: urine | ||
*Mechanism of Action:selectively antagonizes serotonin 5-HT3 receptors | *Mechanism of Action:selectively antagonizes serotonin 5-HT3 receptors | ||
==See Also== | ==See Also== | ||
| Line 60: | Line 81: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:GI]] | [[Category:GI]] | ||
</translate> | |||
Latest revision as of 23:49, 4 January 2026
General
- Type: antiemetics
- Dosage Forms: 4mg, 8mg
- Common Trade Names: Zofran
Adult Dosing
- Nausea/Vomiting: 4-8mg q4h, max 24mg a day
Pediatric Dosing
- Nausea/Vomiting: 0.1mg/kg IV q4h max dose at once:4-8mg, max 24mg
- Gastroenteritis - Vomiting
- 8 to 15 kg:
- 2mg orally disintegrating tablet dissolved orally as a single dose
- 15 to 30 kg:
- 4mg orally disintegrating tablet dissolved orally as a single dose
- Greater than 30 kg:
- 8mg orally disintegrating tablet dissolved orally as a single dose
- 8 to 15 kg:
Special Populations
- Pregnancy Rating: B
- Consider avoiding in 1st trimester; conflicting data regarding possible risk of teratogenicity
- Newer data argues that ondansetron is not the cause of birth defects[1]
- Lactation:safety unknown
- Renal Dosing:
- Adult: not defined
- Pediatric: not defined
- Hepatic Dosing: not defined
- Adult: not defined
- Pediatric: not defined
Contraindications
- Allergy to class/drug
- Congenital long QT syndrome
- Serotonin syndrome
Adverse Reactions
Serious
- bronchospasm
- steven-johnson syndrome
- QT prolongation
- torsades de pointes
- serotonin syndrome
- extrapyramidal symptoms
- blindness, transient
Common
- headache
- constipation
- fatigue
- hypoxia
- fever
- urinary retention
- agitation
Pharmacology
- Half-life: 4.6-5.7 hour
- Metabolism: liver
- Excretion: urine
- Mechanism of Action:selectively antagonizes serotonin 5-HT3 receptors
See Also
References
- ↑ Fejzo MS, et al. Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States. Reprod Toxicol. 2016 Jul;62:87-91.